fda warning about compounded semaglutide July 29, 2024: issued new alert – Partnership for Safe Medicines The FDA Warns of the

it is about potency

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage

Overall, weight loss associated with GLP-1 medications is often a result of the drug reducing the mental and physical cues that tell people to eat

The medication has also been associated with improvements in various cardiometabolic parameters, including blood pressure, glycemic control, and lipid profiles

Think of semaglutide as pressing one appetite-suppression button

the EMA PRAC 2024 review found no causal link between licensed GLP-1 agonists and suicidal ideation, though this cannot be directly applied to retatrutide